Screener
MoonLake Immunotherapeutics MLTX Comprehensive Income (Loss), Net of Tax, Attributable to Parent
Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies
Other financials
Where this comes from
Reported directly by MoonLake Immunotherapeutics in its filing.
Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.
The source filing: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 8:55 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001821586-26-000007
| (in thousands, except share and per share data) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net unrealized gain (loss) on marketable securities and short-term investments | 77 | (2,756) |
| Actuarial gain (loss) on employee benefit plans | (359) | 95 |
| Other comprehensive loss | (282) | (2,661) |
| Comprehensive loss | $(69,989) | $(43,220) |
| Comprehensive loss attributable to controlling interests shareholders | (69,989) | (42,564) |
| Comprehensive loss attributable to noncontrolling interests | — | (656) |
| Weighted-average number of Class A Ordinary Shares, basic and diluted | 71,273,650 | 63,233,788 |
| Basic and diluted net loss per share attributable to controlling interests shareholders | $(0.98) | $(0.63) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is MoonLake Immunotherapeutics's comprehensive income (loss), net of tax, attributable to parent?
- MoonLake Immunotherapeutics (MLTX) reported comprehensive income (loss), net of tax, attributable to parent of -$69.99M in Q1 2026.
- How has MoonLake Immunotherapeutics's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
- MoonLake Immunotherapeutics's comprehensive income (loss), net of tax, attributable to parent decreased by 64.4% year-over-year, from -$42.56M to -$69.99M.
- What is the long-term trend for MoonLake Immunotherapeutics's comprehensive income (loss), net of tax, attributable to parent?
- Over 3 years (2022 to 2025), MoonLake Immunotherapeutics's comprehensive income (loss), net of tax, attributable to parent has grown at a 61.9% compound annual growth rate (CAGR), from -$54.6M to -$231.73M.
- What does comprehensive income (loss), net of tax, attributable to parent mean?
- This metric represents the total change in equity from all sources, combining both net income and other comprehensive income items. It serves as the ultimate measure of the company's financial growth or contraction during the reporting period. By including all gains and losses, it offers a holistic view of the company's total economic value movement.
Ask your AI about MoonLake Immunotherapeutics's comprehensive income (loss), net of tax, attributable to parent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude